___

• KSonmez A, Yumuk V, Haymana C, et al. Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity Study). Obes Facts. 2019;12:167-78.
• Society of Endocrinology and Metabolism of Turkey. Obesity Diagnosis and Treatment Guideline ISBN: 978-605-4011-31-5.2018;80-6.
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study:a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155.
• Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss andAdverse Events: A Systematic Review and Meta-analysis. JAMA 2016;315:2424.
• Rosenbaum M, Hirsch J, Gallagher DA, et al. Long-term persistence of adaptive thermogenesis in subjects who havemaintained a reduced body weight. Am J Clin Nutr. 2008;88:906.
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597.
• Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8:402-24.
• Ara R, Blake L, Gray L, et al. What is the clinical effectiveness and costeffectiveness of using drugs in treating obesepatients in primary care? A systematic review. Health Technol Assess. 2012;16.
• Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin: a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577–87.
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426–36.
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.
• https://www.fda.gov/media/135189/download Access date 14.02.2020.
• Bray GA, Tartaglia LA, Bray GA, et al. Medi-cinal strategies in the treatment of obesity. Nature 2000;404:672.
• Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532.
• Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary carerelevant treatments for obesity in adults: asystematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:434.
• Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123.
• Yancy WS Jr, Westman EC, McDuffie JR, et al. A randomized trial of a lowcarbohydrate diet vs orlistat plus a low-fat diet for weight loss. Arch Intern Med. 2010;170:136-45
• Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids andlipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol. 1994;46:405.
• Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004:CD004094.
• Douglas IJ, Langham J, Bhaskaran K, et al. Orlistat and the risk of acute liver injury: self controlled case series study in UKClinical Practice Research Datalink. BMJ 2013;346:1936.
• MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003;37:510.-2
• https://www.uptodate.com/contents/orlistat-drug-information?search =orlistat&source=panel_search_result&selectedTitle=1~31&usage_ type=panel&kp_tab=drug_general&display_rank=1 access date 23.04.2021
• Singh A, Sarkar SR, Gaber LW, et al. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis. 2007;49:153.
• Weir MA, Beyea MM, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171:703.
• Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7:92-107.
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015;314:687
• Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606.
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11.
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. (Lond) 2013;37:1443.
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311.
• Mali G, Ahuja V, Dubey K. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2021;46:99-105.
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combinationon weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled,phase 3 trial. Lancet. 2011;377:1341.
• 2 new drugs for weight loss. Med Lett Drugs Ther. 2012;54:69-71.
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/ topiramate in severely obese adults: arandomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330.
• https://www.uptodate.com/contents/obesity-in-adults-drug-therapy?s earch=obesity&source=search_result&selectedTitle=7~150&usage_ type=default&display_rank=7 access date 23.04.2021
• Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav. 2010;97:63-83.
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obeseadults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595.
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935.
• . Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/ bupropion SR combination therapy as an adjunct tobehavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110.
• Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/ bupropion sustained-release for the management ofobesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419.
• Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity withmonotherapy and placebo. J Clin Endocrinol Metab. 2009;94:4898.
• Pi-Sunyer X, Apovian CM, McElroy SL, et al. Psychiatric adverse events and effects on mood with prolonged-releasenaltrexone/bupropion combination therapy: a pooled analysis. Int J Obes. (Lond) 2019;43:2085.
• Sharfstein JM, Psaty BM. Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted. JAMA. 2016;315:984.
• Nissen SE, Wolski KE, Prcela L, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweightand Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016;315:990.
• Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151.
• Kim KK, Cho HJ, Kang HC, et al. Effects on weight reduction and safety of short-term phentermine administration in Koreanobese people. Yonsei Med J. 2006;47:614.
• Kang JG, Park CY, Kang JH, et al. Randomized controlled trial to investigate the effects of a newly developed formulation ofphentermine diffuse-controlled release for obesity. Diabetes Obes Metab. 2010;12:876.
• Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med. 1993;119:707.
• McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patientswith hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000;160:2185.
• Caterson I, Coutinho W, Finer N, et al. Early response to sibutramine in patients not meeting current label criteria:preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010;18:987.
• James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obesesubjects. N Engl J Med. 2010;363:905.
• Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:1826.
• Smith SR, Prosser WA, Donahue DJ, et al. APD356004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring). 2009;17:494-503.
• Jurgens TM, Whelan AM, Killian L, et al. Green tea for weight loss and weight maintenance in overweight or obese adults.Cochrane Database Syst Rev. 2012;12:CD008650.
• Onakpoya I, Hung SK, Perry R, et al. The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight loss Supplement: ASystematic Review and Meta-Analysis of Randomised Clinical Trials. J Obes. 2011;2011:509038.